Panobacumab

Monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa

^NY (what is this?) (verify)

Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.^[1]

It is a fully human pentameric IgM antibody with a mouse J chain.^[1]

Development

Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.^[2]

The mechanism of action is as a lipopolysaccharide inhibitor.^[2]

^ ^a ^b International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
^ ^a ^b "Panobacumab - Aridis Pharmaceuticals - AdisInsight". Retrieved 15 November 2019.

Monoclonal antibodies for infectious disease and toxins

Fungal

Human	Efungumab^†

Viral

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Pemivibart Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§